The objective of this research is the development of a systematic approach to the design and optimization of prodrug based topical therapy. Prodrugs of the antiviral agent, 9-Beta-D-arabinofuranosyladenine (vidarabine, ara-A), with be investigated by means of a novel approach based upon concepts and techniques of physical chemistry which permit factoring out the various physical and biochemical processes influencing the delivery of the active form of the drug to the target sites. Transport and metabolism studies aimed at determining and/or predicting the target site concentrations of the vidarabine species for a variety of recently synthesized vidarabine prodrugs will be conducted. The studies will include experiments with the hairless mouse skin and the vaginal membrane of the guinea pig. The data analysis will involve the use of the recently developed methods of physical chemistry for handling the relatively complex problem of simultaneous diffusion and enzymatic reactions for a multi-component system in biological membranes and tissues. Additionally, flux dependence studies will be conducted with hairless mice and with guinea pigs to determine steady-state target tissue species concentration profiles and blood levels of the various vidarabine species for different prodrug delivery rates when vidarabine and its prodrugs are administered topically and when they are administered systemically. The data provided from the above will be compared to the results of flux/response studies on the efficacy of the prodrugs of ara-A in the topical treatment of herpes simplex virus (HSV) type 1 cutaneous infections in hairless mice and in the topical treatment of HSV type 2 genital infections in guinea pigs. The following outcomes from these studies are expected: (1) the differentiation between analog effects (the prodrug itself having an intrinsic effect) and prodrug effects (the prodrug serving as a precursor to the active species); (2) from infected animal studies with both topical and systemic administration, the determination of the locale to which the active moiety must be delivered to achieve its activity; and (3) based on (1) and (2), above, the determination of prodrug/delivery system combinations with optimal therapeutic activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI020161-03A2
Application #
3129647
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1982-11-01
Project End
1988-11-30
Budget Start
1985-12-01
Budget End
1986-11-30
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Utah
Department
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Mehta, S C; Afouna, M I; Ghanem, A H et al. (1997) Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug. J Pharm Sci 86:797-801
Patel, P J; Ghanem, A H; Higuchi, W I et al. (1996) Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept. Antiviral Res 29:279-86
Imanidis, G; Song, W Q; Lee, P H et al. (1994) Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice. Pharm Res 11:1035-41
Lee, P H; Su, M H; Kern, E R et al. (1992) Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice. Pharm Res 9:979-89
Komada, F; Imanidis, G; Miyajima, M et al. (1991) Design of 9-beta-D-arabinofuranosyladenine (ara-A) transdermal delivery system for animal studies: regulation of drug concentration in vivo. J Pharm Sci 80:935-41
Shannon, W M; Westbrook, L; Higuchi, W I et al. (1985) Influence of 1-dodecylazacycloheptan-2-one (Azone) on the topical therapy of cutaneous herpes simplex virus type 1 infection in hairless mice with 2',3'-di-O-acetyl-9-beta-D-arabinofuranosyladenine and 5'-O-valeryl-9-beta-D-arabinofuranosyladenine. J Pharm Sci 74:1157-61
Anderson, B D; Fung, M C; Kumar, S D et al. (1985) Hydrolysis and solvent-dependent 2'----5'and 3'----5' acyl migration in prodrugs of 9-beta-D-arabinofuranosyladenine. J Pharm Sci 74:825-30